Patents by Inventor Sophie-Dorothee Clas

Sophie-Dorothee Clas has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Alternative forms of the phosphodiesterase-4 inhibitor N-cyclopropyl-1-{3-[(1-oxidopryidin-3-yl)ethynyl]phenyl}-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxyamide
    Patent number: 8552193
    Abstract: The present invention is directed to alternative forms of the title phosphodiesterase 4 inhibitor which has the structural formula shown immediately below:
    Type: Grant
    Filed: March 31, 2010
    Date of Patent: October 8, 2013
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Sophie-Dorothee Clas, Rafik Naccache, Hongshi Yu, Jerry Murry, Narayan Vanankaval
  • ALTERNATIVE FORMS OF THE PHOSPHODIESTERASE-4 INHIBITOR N-CYCLOPROPYL-1--4-OXO-1,4-DIHYDRO-1,8-NAPHTHYRIDINE-3-CARBOXYAMIDE
    Publication number: 20130231363
    Abstract: The present invention is directed to alternative forms of the title phosphodiesterase 4 inhibitor which has the structural formula shown immediately below:
    Type: Application
    Filed: March 31, 2010
    Publication date: September 5, 2013
    Inventors: Sophie-Dorothee Clas, Rafik Naccache, Hongshi Yu, Jerry Murry, Narayan Variankaval
  • Alternative Forms of the Phosphodiesterase-4 Inhibitor N-Cyclopropyl-1--4-Oxo-1,4-Dihydro-1,8-Naphthyridine-3-Carboxyamide
    Publication number: 20110245290
    Abstract: The present invention is directed to alternative forms of the title phosphodiesterase 4 inhibitor which has the structural formula shown immediately below:
    Type: Application
    Filed: March 31, 2010
    Publication date: October 6, 2011
    Inventors: Sophie-Dorothee Clas, Rafik Naccache, Hongshi Yu, Jerry Murry, Narayan Variankaval
  • Polymorphic form of montelukast sodium
    Patent number: 7560559
    Abstract: The invention provides novel polymorphic form of montelukast sodium, as well as methods of using and pharmaceutical compositions containing saud novel form. Also provided are montelukast sodium: acetonitrile solvates, which are intermediates in the formation of crystalline montelukast sodium.
    Type: Grant
    Filed: April 12, 2004
    Date of Patent: July 14, 2009
    Assignees: Merck & Co., Inc., Merck Frosst Canada & Co.
    Inventors: Jun-Hong Chou, Michael B. Gentzler, James N. Michaels, Cynthia Bazin, Sophie-Dorothee Clas, Chad Dalton, Michael Guojie Wu
  • Altenrative Forms Of The Phosphodeisterase -4 Inhibitor N-Cyclopropyl-1- -3{3-[(1-Oxidopyryidin-3-Yl) Phenyl]-4-Oxo-1,4-Dihydro-1,8-Naphthyridine-3-Carboxyamide
    Publication number: 20080119509
    Abstract: The present invention is directed to alternative forms of the title phosphodiesterase 4 inhibitor which has the structural formula shown immediately below: Compound IX
    Type: Application
    Filed: April 22, 2005
    Publication date: May 22, 2008
    Inventors: Sophie-Dorothee Clas, Rafik Naccache, Hongshi Yu, Jerry Murry, Narayan Variankaval
  • Polymorphic form of montelukast sodium
    Publication number: 20060194838
    Abstract: The invention provides novel polymorphic form of montelukast sodium, as well as methods of using and pharmaceutical compositions containing saud novel form. Also provided are montelukast sodium: acetonitrile solvates, which are intermediates in the formation of crystalline montelukast sodium.
    Type: Application
    Filed: April 12, 2004
    Publication date: August 31, 2006
    Inventors: Jun-Hong Chou, Michael Gentzler, James Michaels, Cynthia Bazin, Sophie-Dorothee Clas, Chad Dalton, Michael Wu
  • Substituted 8-arylquinoline phosphodiesterase-4 inhibitors
    Patent number: 6740666
    Abstract: Novel sulfuric acid, methanesulfonic acid, p-toluenesulfonic acid, 2-naphthalenesulfonic acid, hydrochloride acid, or benzenesulfonic acid salts of substituted 8-arylquinolines, wherein the aryl group at the 8-position contains a substituent substituted-alkenyl group, are PDE4 inhibitors.
    Type: Grant
    Filed: November 9, 2001
    Date of Patent: May 25, 2004
    Assignees: Merck & Co., Inc., Merck Frosst Canada & Co.
    Inventors: Dwight Macdonald, Helene Perrier, Roch Thibert, Guo-Jie Ho, Anant Vailaya, David Conlon, Elizabeth Kwong, Sophie-Dorothee Clas
  • Substituted 8-arylquinoline phosphodiesterase-4 inhibitors
    Publication number: 20020143032
    Abstract: Novel sulfuric acid, methanesulfonic acid, p-toluenesulfonic acid, 2-naphthalenesulfonic acid, hydrochloride acid, or benzenesulfonic acid salts of substituted 8-arylquinolines, wherein the aryl group at the 8-position contains a substituent substituted-alkenyl group, are PDE4 inhibitors.
    Type: Application
    Filed: November 9, 2001
    Publication date: October 3, 2002
    Inventors: Dwight Macdonald, Helene Perrier, Roch Thibert, Guo-Jie Ho, Anant Vailaya, David Conlon, Elizabeth Kwong, Sophie-Dorothee Clas
  • Polymorphic, amorphous and hydrated forms of 5-chloro-3-(4-methanesulfonyphenyl)-6'- methyl-[2,3']bipyridinyl
    Patent number: 6441002
    Abstract: Polymorphic, amorphous and hydrated forms of the title compound having the following structure: are disclosed. The compound is a potent and selective cyclooxygenase-2 (COX-2) inhibitor.
    Type: Grant
    Filed: November 28, 2000
    Date of Patent: August 27, 2002
    Assignees: Merck & Co., Inc., Merck Frosst Canada & Co.
    Inventors: Sophie Dorothee Clas, Louis S. Crocker, James A. McCauley, Ian Davies, Chad Dalton
  • Synthesis of 4-[(5-substituted phenyl)-3-substituted-1H-pyrazol-1-yl]benzenesulfonamide
    Patent number: 6232472
    Abstract: This invention encompasses a novel process for synthesizing the compound represented by formula I: These compounds are useful as non-steroidal anti-inflammatory agents.
    Type: Grant
    Filed: September 13, 2000
    Date of Patent: May 15, 2001
    Assignee: Merck Frosst Canada & Co.
    Inventors: Paul O'Shea, Xin Wang, Richard D. Tillyer, Sophie-Dorothee Clas, Chad Dalton
  • Synthesis of 4-[5-substituted or unsubstituted phenyl)-3-substituted-1H-pyrazol-1-yl]benzenesulfonamides
    Patent number: 6150534
    Abstract: This invention encompasses a novel process for synthesizing the compound represented by formula I: ##STR1## These compounds are useful as non-steroidal anti-inflammatory agents.
    Type: Grant
    Filed: January 14, 2000
    Date of Patent: November 21, 2000
    Assignee: Merck Frosst Canada & Co.
    Inventors: Paul O'Shea, Richard D. Tillyer, Xin Wang, Sophie-Dorothee Clas, Chad Dalton
  • Ingestible polymeric phosphonium salts, composition thereof and method of treating hypercholesterolemia
    Patent number: 5427777
    Abstract: Novel ingestible polymeric phosphonium salts have the formula: ##STR1## wherein P' represents a cross-linked and non-digestible polymer backbone; R is a lower alkyl radical; X.sup.- is a pharmaceutically acceptable anion; n, n.sub.1 and n.sub.2 are, independently, integers varying from 0 to 6 inclusive, with the proviso that when m.sub.1 .gtoreq.1, n.sub.2 .gtoreq.1; and o.sub.1, o.sub.2, p.sub.1 p.sub.2, q.sub.1 and q.sub.2 are, independently, integers varying from 1 to 6 inclusive. The polymeric phosphonium salts of the invention are highly efficient sorbents for bile acids and salts and can thus be used for reducing hypercholesterolemia in affected humans.
    Type: Grant
    Filed: March 23, 1992
    Date of Patent: June 27, 1995
    Assignee: Lowchol Scientific, Inc.
    Inventors: Leon E. St. Pierre, George R. Brown, Zhanjie Tan, Sophie-Dorothee Clas